Gene Therapy: Dual Supramolecular Nanoparticle Vectors Enable CRISPR/Cas9‐Mediated Knockin of Retinoschisin 1 Gene—A Potential Nonviral Therapeutic Solution for X‐Linked Juvenile Retinoschisis (Adv. Sci. 10/2020)

• Published in: Advanced science Vol. 7; no. 10
• Main Authors: Chou, Shih‐Jie, Yang, Peng, Ban, Qian, Yang, Yi‐Ping, Wang, Mong‐Lien, Chien, Chian‐Shiu, Chen, Shih‐Jen, Sun, Na, Zhu, Yazhen, Liu, Hongtao, Hui, Wenqiao, Lin, Tai‐Chi, Wang, Fang, Zhang, Ryan Yue, Nguyen, Viet Q., Liu, Wenfei, Chen, Mengxiang, Jonas, Steve J., Weiss, Paul S., Tseng, Hsian‐Rong, Chiou, Shih‐Hwa
• Format: Journal Article
• Language: English
• Published: Weinheim John Wiley & Sons, Inc 20-05-2020; John Wiley and Sons Inc
• Subjects: codelivery; CRISPR/Cas9; Frontispiece; Gene therapy; retina; supramolecular nanoparticles; X‐linked juvenile retinoschisis
• ISSN: 2198-3844; 2198-3844
• DOI: 10.1002/advs.202070054

In article number 1903432, Shih‐Hwa Chiou, Hsian‐Rong Tseng, Paul S. Weiss, and co‐workers introduce an in vivo CRISPR/Cas9‐mediated knockin approach using two supramolecular nanoparticle (SMNP) vectors. By intravitreally injecting the two SMNP vectors into the mouse eyes, the RS1/GFP gene is knocked into the Rosa26 site in mice retinas, offering a revolutionarily curative therapeutic solution for X‐linked juvenile retinoschisis.